Treatment of Nausea and Emesis During Cancer Chemotherapy Sussanne Börjeson, RN, PhD, Timo J Hursti, DrMedSc, Carol Tishelman, RN, DrMedSc, Curt Peterson, MD, PhD, Gunnar Steineck, MD, PhD Journal of Pain and Symptom Management Volume 24, Issue 3, Pages 345-358 (September 2002) DOI: 10.1016/S0885-3924(02)00543-2
Figure 1 a. Proportions (%) of patients in each group free from acute nausea during cycles 1–4. b. Proportions (%) of patients in each group free from delayed nausea during cycles 1–4. Journal of Pain and Symptom Management 2002 24, 345-358DOI: (10.1016/S0885-3924(02)00543-2)
Figure 1 a. Proportions (%) of patients in each group free from acute nausea during cycles 1–4. b. Proportions (%) of patients in each group free from delayed nausea during cycles 1–4. Journal of Pain and Symptom Management 2002 24, 345-358DOI: (10.1016/S0885-3924(02)00543-2)
Figure 2 Mean change from baseline VAS rating of well-being to the ratings in cycles 1–4. A positive change means improved ratings of well-being compared to the baseline assessment. Journal of Pain and Symptom Management 2002 24, 345-358DOI: (10.1016/S0885-3924(02)00543-2)